SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3561 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3336You sound upbeat with your ANLY and REGN collaboration so why do you not predictFelix B-7/16/2021
3335< then the difference in profit sharing will not factor into that decision ofMiljenko Zuanic-7/15/2021
3334Yes, that's a fair point that I should have added too. We are only talking CuttingEdge Bio-7/15/2021
3333Perhaps a flop commercially but SNY was critical in funding REGN in the early daFelix B-7/14/2021
3332Perhaps you misunderstood my comment. What I meant is that if the drug will not CuttingEdge Bio-7/14/2021
3331< If ALNY drug can get distributed to CNS where it needs to go and Abs canMiljenko Zuanic-7/13/2021
3330I am not sure which modality they will utilize, but I will note two things. RighCuttingEdge Bio-7/13/2021
3329I am in from 1996. Axokine was modified CNTF (modified neurotrophic factor), andMiljenko Zuanic-7/12/2021
3328A little before(2003) my time investing in REGN. nytimes.com But this was a repBioBait-7/12/2021
3327<Should be good target for Alnylam. Once every 6m jab to control weight.> Miljenko Zuanic-7/12/2021
3326I used to think, wow, they discovered this target and partnered with Alnylam befCuttingEdge Bio-7/3/2021
3325Stat interview with George Yancoupolous. He mentions the collaboration with IntA.J. Mullen-7/3/2021
3324Should be good target for Alnylam. Once every 6m jab to control weight.Biotechwantabe-7/2/2021
3323What do you think of GPR75? There didn't think there was much fan fare behiFelix B-7/2/2021
3322Guggenheim Biopharma Strategy Series | Biopharma’s Next Decade: Views from the TBiotechwantabe16/30/2021
3321I could be wrong, but I got the impression here that Epic is hoarding data. AndCuttingEdge Bio-6/27/2021
3320Milkeninstitute collaboration Interesting WebEx Biotechwantabe-6/25/2021
3319Libtayo and cemo Combo, I think will be next be catalyst. Interesting patent: HBiotechwantabe-6/18/2021
3318The failures of Regeneron's commercial organization do not constitute scientCuttingEdge Bio-6/18/2021
3317Repatha is not any better than Praluent, unless you fall for deceptive data miniCuttingEdge Bio-6/18/2021
3316What's the next big catalyst for REGN after this event? Results from one ofFelix B-6/17/2021
3315Repatha is better Abs and sell 3X Praluent, without going into details...market Miljenko Zuanic-6/17/2021
3314What makes you say "Repatha BETTER than Praluent" given they both haveFelix B-6/17/2021
3313< I think they know how to make an antibody.> Ya, they do! Are they withoMiljenko Zuanic-6/17/2021
3312This is getting ridiculous now. What Porges is implying is that REGN needs 10x tCuttingEdge Bio-6/17/2021
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News